Replies to post #730032 on NorthWest Biotherapeutics Inc (NWBO)

[Hopeforthefuture3]

Think I do now understand why did not apply with fda. On the presentation on Musellafoundation with Mimivax ceo from July 2023 for next trial they are to randomize 3 to 2 treatment to control. They asked fda (minute 33 or so) if they could use external controls. FDA responded could use external control only if they could find patient level matched controls and they could not find such data. Sad for all the trials that have taken place they do not share the patient level data. Now UK application and not fda makes sense

[dennisdave]

mmmmm

DCVAXL trial
Median OS (mOS) for the 232 patients with nGBM receiving DCVax-L was 19.3 (95% CI, 17.5-21.3) months

SurVaxM is an experimental vaccine for the treatment of brain tumors. Early results from a small trial were recently reported Of 63 patients with newly diagnosed Glioblastoma, the median overall survival was 25.9 months from the first dose of the vaccine,

and not a personalized vaccine so easier to produce